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Cells were stained according to the following procedure: 100 µL of donor whole blood was 
added to appropriately labeled tubes. Surface markers were subsequently stained by adding 
antibody fluorochrome conjugates; to facilitate population identification, respective isotype 
controls were added to control tubes. Tubes were then vortexed and incubated for 20 
minutes in the dark at room temperature. After washing with phosphate-buffered saline 
(PBS) bovine serum albumin (BSA) buffer, tubes were centrifuged and decanted. Two 
milliliters of prewarmed 1× BD lyse/fix solution was then added and tubes were vortexed and 
incubated for 15 minutes in a 37°C water bath. After incubation, tubes were centrifuged and 
the supernatant was decanted and washed with PBS BSA buffer. Then 500 µL of perm 
buffer III was added and incubated according to the manufacturer’s specifications. After 
washing twice, the appropriate antibodies for intracellular staining or isotype controls were 
added with PBS/ BSA buffer and vortexed and incubated for 30 minutes in the dark at room 
temperature. These isotype controls were used to establish background staining and 
determine MDM2 percent cell positivity.  Tubes were washed twice with PBS/ BSA buffer 
and finally resuspended in 500 µL for acquisition in a FACSCanto II flow cytometer (BD 
Biosciences, San Jose, CA, USA). A total of 250,000 events were acquired. 
 
Electronic gating 
Flow cytometry analysis softwares Winlist and Flowjo were used. Initially, a gate is drawn 
around all cells with normal size (forwards scatter) and granular characteristics (side 
scatter): the total nucleated cell gate (TNC; Figure S1). Within this TNC subset, the AML 
blast population is then identified by drawing a region around cells with dim CD45 
expression and low side scatter properties (CD45dim blasts in Figure S1). The blast 
population can be further refined by gating on CD34-positive or CD34-negative blasts 
(Figure S1; CD45dim/CD34+ or CD45dim/CD34− blasts, respectively). The threshold for CD34 




Figure S1. Identification of CD45dim/side scatter (SSC) low blasts and CD34+ blasts by 
electronic gating. The CD45dim general blast population and the more refined blasts that 
additionally express CD34 are displayed in dot plots as shown in Figure S2. The isotype 
control used instead of MDM2 staining can be used to set the threshold for MDM2 positivity 
(upper 2 panels in Figure S2.) The staining conditions, including the MDM2 recognizing 
antibody, are displayed at the bottom of Figure S2. The cell population falling in the regions 
defined as MDM2 positive is determined by calculating the percentage of MDM2-expressing 
cells within the respective blast parent population. TNC, total nucleated cell. 
 
Figure S2. Identification of MDM2-positive cells in the CD45dim blast population and in the 
CD45dim/CD34+ blast population. Isotype controls (upper 2 dot plots) are used to draw the 
borders for MDM2 threshold positivity. SSC, side scatter. 
 
  
Table S1. Patient information 
Characteristics CR Non-CR All P value 
No. of patients 26 66 92 NA 
Age, mean (SD), years 62 (11) 60 (13) 60 (12) .61 
Sex, male (female), % 62 (38) 61 (39) 61 (39) 1 
Race, white (nonwhite), % 73 (27) 89 (11) 85 (15) .98 
ECOG PS 2 (1, 0), % 0 (46, 54) 9 (67, 24) 7 (61, 33) .017 
TP53, mutant (wild type), % 4 (96) 26 (74) 2 (80) .018 
Treatment, monotherapy 
(combination), % 
20 (80) 42 (58) 36 (64) .084 
 
All statistical analyses were conducted with R 3.0.2 software. The Wilcoxon rank-sum test 
was used to examine marginal association between the clinical responses and continuous 
variables such as MDM2 flow measurements and age. Fisher exact test was used to 
examine marginal association between the clinical responses and the categorical variables. 
Area under the concentration curve of receiver-operating characteristic was calculated to 
indicate complete remission (CR)/non-CR classification performance, with 95% CI calculated 
with bootstrapping. Logistic regression was adopted to adjust baseline demographic 
variables and treatment effects (monotherapy or combination therapy). Vuong test was used 
to compare models with different MDM2 flow measurements. All reported P values are 2 
sided (P significant < .05). ECOG PS, Eastern Cooperative Oncology Group performance 
status; NA, not applicable. 
  
 
